ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Mike108
|
261 |
63K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
63K
|
6
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
Mike108
|
49 |
14K |
13 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
49
|
14K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Mike108
|
58 |
17K |
26 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
58
|
17K
|
26
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
Mike108
|
196 |
36K |
2 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
196
|
36K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
Mike108
|
100 |
26K |
11 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
26K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Mike108
|
1.3K |
326K |
13 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Mike108
|
114 |
33K |
7 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
Mike108
|
45 |
13K |
19 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
45
|
13K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
Mike108
|
197 |
51K |
17 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
197
|
51K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
Mike108
|
323 |
75K |
5 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
323
|
75K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Balance of PAAOA holders as at 29 December 2023
|
|
Mike108
|
6 |
1.7K |
1 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
6
|
1.7K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
Mike108
|
91 |
18K |
21 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
91
|
18K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
Mike108
|
126 |
28K |
9 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
126
|
28K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
Mike108
|
200 |
41K |
13 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
200
|
41K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Mike108
|
396 |
82K |
11 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
396
|
82K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
Mike108
|
396 |
82K |
16 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
82K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust launches international CEO search
|
|
Mike108
|
95 |
23K |
16 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
95
|
23K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Suspension from Official Quotation
|
|
Mike108
|
59 |
16K |
8 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
59
|
16K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Monepantel Trial Achieves Successful Anti-Cancer Outcome
|
|
Mike108
|
438 |
119K |
10 |
15/05/20 |
15/05/20 |
ASX - By Stock
|
438
|
119K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Monepantel Trial Achieves Successful Anti-Cancer Outcome
|
|
Mike108
|
438 |
119K |
17 |
12/05/20 |
12/05/20 |
ASX - By Stock
|
438
|
119K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Mike108
|
202 |
63K |
6 |
11/05/20 |
11/05/20 |
ASX - By Stock
|
202
|
63K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
For the 300 , Keep The Faith
|
|
Mike108
|
369 |
234K |
10 |
09/02/20 |
09/02/20 |
ASX - By Stock
|
369
|
234K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
For the 300 , Keep The Faith
|
|
Mike108
|
369 |
234K |
13 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
369
|
234K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
For the 300 , Keep The Faith
|
|
Mike108
|
369 |
234K |
14 |
27/01/20 |
27/01/20 |
ASX - By Stock
|
369
|
234K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
2020 Hindsight
|
|
Mike108
|
32 |
11K |
3 |
06/01/20 |
06/01/20 |
ASX - By Stock
|
32
|
11K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
|
|
Mike108
|
52 |
20K |
12 |
11/12/19 |
11/12/19 |
ASX - By Stock
|
52
|
20K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Pitt Street Research Life Sciences Conference
|
|
Mike108
|
15 |
8.9K |
6 |
28/11/19 |
28/11/19 |
ASX - By Stock
|
15
|
8.9K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust Phase II K9 Trial
|
|
Mike108
|
559 |
240K |
16 |
12/10/19 |
12/10/19 |
ASX - By Stock
|
559
|
240K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Long term considerations
|
|
Mike108
|
83 |
88K |
15 |
14/08/19 |
14/08/19 |
ASX - By Stock
|
83
|
88K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Monepantel Principal Metabolite Shows Anti-Cancer Activity
|
|
Mike108
|
47 |
19K |
8 |
14/01/19 |
14/01/19 |
ASX - By Stock
|
47
|
19K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
Mike108
|
59 |
27K |
7 |
16/04/18 |
16/04/18 |
ASX - By Stock
|
59
|
27K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cleansing Notice
|
|
Mike108
|
13 |
5.9K |
11 |
02/04/18 |
02/04/18 |
ASX - By Stock
|
13
|
5.9K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Shareholders Update
|
|
Mike108
|
13 |
6.3K |
2 |
22/08/17 |
22/08/17 |
ASX - By Stock
|
13
|
6.3K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Biotech growth story....hideously oversold
|
|
Mike108
|
21 |
8.8K |
3 |
03/08/17 |
03/08/17 |
ASX - By Stock
|
21
|
8.8K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C - Quarterly Report & Brief Company Update
|
|
Mike108
|
28 |
10K |
3 |
01/08/17 |
01/08/17 |
ASX - By Stock
|
28
|
10K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Possible breakout
|
|
Mike108
|
129 |
43K |
4 |
24/07/17 |
24/07/17 |
ASX - By Stock
|
129
|
43K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Possible breakout
|
|
Mike108
|
129 |
43K |
1 |
08/05/17 |
08/05/17 |
ASX - By Stock
|
129
|
43K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C - Quarterly Report & Company Update - March 2017
|
|
Mike108
|
23 |
10K |
0 |
16/04/17 |
16/04/17 |
ASX - By Stock
|
23
|
10K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C - Quarterly Report & Company Update - March 2017
|
|
Mike108
|
23 |
10K |
0 |
15/04/17 |
15/04/17 |
ASX - By Stock
|
23
|
10K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Bella's results on MPL
|
|
Mike108
|
32 |
13K |
2 |
07/04/17 |
07/04/17 |
ASX - By Stock
|
32
|
13K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Bella's results on MPL
|
|
Mike108
|
32 |
13K |
9 |
02/04/17 |
02/04/17 |
ASX - By Stock
|
32
|
13K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Gift
|
|
Mike108
|
26 |
11K |
4 |
08/12/16 |
08/12/16 |
ASX - By Stock
|
26
|
11K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Phase II Strategy Update
|
|
Mike108
|
11 |
4.9K |
5 |
21/11/16 |
21/11/16 |
ASX - By Stock
|
11
|
4.9K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Manipulation attempts ?
|
|
Mike108
|
5 |
2.3K |
1 |
28/10/16 |
28/10/16 |
ASX - By Stock
|
5
|
2.3K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
biotech bounce
|
|
Mike108
|
1 |
1.1K |
2 |
18/10/16 |
18/10/16 |
ASX - By Stock
|
1
|
1.1K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Phase II Canine Trial begins at University of Cambridge-PAA.AX
|
|
Mike108
|
28 |
8.9K |
2 |
19/09/16 |
19/09/16 |
ASX - By Stock
|
28
|
8.9K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: IP exchange with UNSW consolidates MPL patent position-PAA.AX
|
|
Mike108
|
15 |
3.5K |
2 |
08/08/16 |
08/08/16 |
ASX - By Stock
|
15
|
3.5K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Mandate signed to raise capital in USA & list on NASDAQ-PAA.AX
|
|
Mike108
|
17 |
5.4K |
1 |
02/06/16 |
02/06/16 |
ASX - By Stock
|
17
|
5.4K
|
1
|
|
ASX - By Stock
|
CVV |
Re:
Ann: Listed Options Expiring 31 May 2016-CVV.AX
|
|
Mike108
|
1 |
1.7K |
0 |
04/05/16 |
04/05/16 |
ASX - By Stock
|
1
|
1.7K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Respected Florida based US research house Redchip, has re-rated ASX listed cancer drug hopeful Pharm
|
|
Mike108
|
26 |
7.7K |
2 |
15/04/16 |
15/04/16 |
ASX - By Stock
|
26
|
7.7K
|
2
|
|